Possible involvement of Akt activity in endothelial dysfunction in type 2 diabetic mice

Journal of Pharmacological Sciences

Volumn 106, Issue 4, 2008, Pages 600-608

  Takenouchi, Yasuhiro ^a   Kobayashi, Tsuneo ^a   Matsumoto, Takayuki ^a   Kamata, Katsuo ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Akt; Diabetes; Endothelial cell; Phosphatase and tensin homolog deleted on chromosome ten (PTEN); Statin

Indexed keywords

ADRENOMEDULLIN; CHOLESTEROL; CLONIDINE; ENDOTHELIUM DERIVED RELAXING FACTOR; GLUCOSE; INSULIN; NICOTINAMIDE; NITRATE; NITRIC OXIDE; NITRITE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; SIMVASTATIN; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CHROMOSOME 10; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE DELETION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY; SYSTOLIC BLOOD PRESSURE;

EID: 42349091801     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0071684     Document Type: Article

References (44)

1. Cohen RA. The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Prog Cardiovasc Dis. 1995;38:105-128.
2. Eckel RH, Wassef M, Chait A, Sobel B, Barrett E, King G, et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: Pathogenesis of atherosclerosis in diabetes. Circulation. 2002;105:e138-e143.
3. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-376.
4. Peach MJ, Loeb AL, Singer HA, Saye J. Endothelium-derived vascular relaxing factor. Hypertension. 1985;7:I 94-I 100.
5. Kamata K, Kanie N, Inose A. Mechanisms underlying attenuated contractile response of aortic rings to noradrenaline in fructosefed mice. Eur J Pharmacol. 2001;428:241-249.
6. Pannirselvam M, Verma S, Anderson TJ, Triggle CR. Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (db/db-/-) mice: role of decreased tetrahydrobiopterin bioavailability. Br J Pharmacol. 2002;136:255-263.
7. 2+ mobilization in the aortic endothelium in streptozotocin-induced diabetic and cholesterol-fed mice. Br J Pharmacol. 1998;123:1509-1516.
8. Kuchan MJ, Frangos JA. Role of calcium and calmodulin in flow-induced nitric oxide production in endothelial cells. Am J Physiol. 1994;266:C628-C636.
9. 2+mobilization. Circ Res. 1997;81:885-892.
10. Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int. 1994;45:598-604.
11. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601-605.
12. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399:597-601.
13. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol Heart Circ Physiol. 1998;274:H1054-H1058.
14. Nishimatsu H, Suzuki E, Nagata D, Moriyama N, Satonaka H, Walsh K, et al. Adrenomedullin induces endothelium-dependent vasorelaxation via the phosphatidylinositol 3-kinase/Akt-dependent pathway in rat aorta. Circ Res. 2001;89:63-70.
15. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000;101:1539-1545.
16. Kobayashi T, Matsumoto T, Kamata K. The PI3-K/Akt pathway: roles related to alterations in vasomotor responses in diabetic models. J Smooth Muscle Res. 2005;41:283-302.
17. Kobayashi T, Taguchi K, Yasuhiro T, Matsumoto T, Kamata K. Impairment of PI3-K/Akt pathway underlies attenuated endothelial function in aorta of type 2 diabetic mouse model. Hypertension. 2004;44:956-962.
18. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest. 1996;97:2601-2610.
19. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest. 1999;104:447-457.
20. Bradfute DL, Simoni RD. Non-sterol compounds that regulate cholesterogenesis. Analogues of farnesyl pyrophosphate reduce 3-hydroxy-3-methylglutaryl-coenzyme A reductase levels. Nature. 1990;343:425-430.
21. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
22. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res. 2001;49:281-287.
23. Mason RP, Walter MF, Jacob RF. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation. 2004;109:II34-II41.
24. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol. 2000;20:61-69.
25. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2001;7:129.
26. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res. 2002;90:1243-1250.
27. Kobayashi T, Hayashi Y, Taguchi K, Matsumoto T, Kamata K. ANG II enhances contractile responses via PI3-kinase p110 delta pathway in aortas from diabetic rats with systemic hyperinsulinemia. Am J Physiol Heart Circ Physiol. 2006;291:H846-H853.
28. Matsumoto T, Miyamori K, Kobayashi T, Kamata K. Apocynin normalizes hyperreactivity to phenylephrine in mesenteric arteries from cholesterol-fed mice by improving endothelium-derived hyperpolarizing factor response. Free Radic Biol Med. 2006;41:1289-1303.
29. Kurup S, Bhonde RR. Combined effect of nicotinamide and streptozotocin on diabetic status in partially pancreatectomized adult BALB/c mice. Horm Metab Res. 2000;32:330-334.
30. Masiello P, Broca C, Gross R, Roye M, Manteghetti M, Hillaire-Buys D, et al. Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes. 1998;47:224-229.
31. Matsumoto T, Wakabayashi K, Kobayashi T, Kamata K. Alterations in vascular endothelial function in the aorta and mesenteric artery in type II diabetic rats. Can J Physiol Pharmacol. 2004;82:175-182.
32. Novelli M, Fabregat ME, Fernandez-Alvarez J, Gomis R, Masiello P. Metabolic and functional studies on isolated islets in a new rat model of type 2 diabetes. Mol Cell Endocrinol. 2001;175:57-66.
33. Ahmed M, Griffiths P. Statins and secondary prevention of coronary heart disease. Br J Community Nurs. 2004;9:160-165.
34. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, et al. Simvastatin has antiinflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol. 2001;21:115-121.
35. Jiang J, Roman RJ. Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension. 1997;30:968-974.
36. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377:239-242.
37. Hirsch E, Katanaev VL, Garlada C, Azzolino O, Pirola L, Silego L, et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science. 2000;287:1049-1053.
38. Leopoldt D, Hanck T, Exner T, Maier U, Wetzker R, Nurnberg B. Gbetagammma stimulates phosphoinositide 3-kinase-gammma by direct interaction with two domains of the catalytic p110 subunit. J Biol Chem. 1998;273:7024-7029.
39. Bockman CS, Gonzalez-Cabrera I, Abel PW. Alpha-2 adrenoceptor subtype causing nitric oxide-mediated vascular relaxation in rats. J Pharmacol Exp Ther. 1996;278:1235-1243.
40. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273:13375-13378.
41. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997;7:261-269.
42. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002;14:381-395.
43. Leslie NR, Downes CP. PTEN: the down side of PI 3-kinase signalling. Cell Signal. 2002;14:285-295.
44. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95:29-39.